La presente informativa è resa, anche ai sensi dell’art. 13 del D. Lgs. 196/2003 “Codice in materia di protezione dei dati personali” (“Codice Privacy”) 
e degli artt. 13 e 14 del Regolamento (UE) 2016/679 (“GDPR”), a coloro che si collegano alla presente edizione online del giornale Tribuna Economica di proprietà di AFC Editore Soc. Coop. 

Leggi di più

I TWEET

@BMWItalia @BMW è Partner Ufficiale del @teatroallascala di #Milano per lo speciale Concerto del 7 dicembre… https://t.co/2euw51TwGg
RT @ItalyMFA: "Pronto ed entusiasta di lavorare con l'#Algeria per affrontare le sfide comuni regionali e globali [...]" Buon lavoro a Gio…
5 Accordi per l’innovazione e di sviluppo. Dal @MISE_GOV 61 milioni di euro per progetti in #Campania, #Lombardiahttps://t.co/uSDdxJKcM6
@SACEgroup sostiene l’#automotive che rappresenta il 6,2% del Pil e il 7% dell’occupazione del manifatturiero nazi… https://t.co/2sFHy32Mlf
Andamento del settore #Automotive e trend dell’export. Continua la fase critica https://t.co/takL9c7sni’export-con… https://t.co/fEO34p223o

The European Investment Bank (EIB) will provide financing of €25 million to the Austrian biotech company Apeiron Biologics AG (Apeiron). The financing will support the development of new pharmaceutical products to treat cancer, particularly a rare type affecting children. The transaction with Apeiron was made possible

by the support of the European Fund for Strategic Investments (EFSI). EFSI is the central pillar of the Investment Plan for Europe, in which the EIB Group and the European Commission as strategic partners aim to boost the competitiveness of the European economy.

Andrew McDowell, Vice President of the EIB and responsible for Austria, commented: “The EU bank’s investments, especially in SMEs at the cutting edge of R&D, are key to help strengthen Europe’s competitiveness and foster sustainable growth. Our transaction with Apeiron demonstrates such support. Apeiron is an innovative biotech company targeting areas of significant unmet medical need. Our loan, in particular through its long tenor and its favorable financing conditions, is a high added-value transaction, as it enables Apeiron to significantly increase its R&D activities. This will create 5-10 highly qualified jobs and will increase Apeiron’s workforce by up to 25 percent.”

Hans Loibner, Chief Executive Officer of Apeiron, commented: “We are very pleased about the fact that the EIB has recognised Apeiron’s potential for further groundbreaking R&D. Our recent achievement of obtaining the EU marketing authorisation for our most advanced project in combination with access to additional funding through the EIB forms a very promising basis for our company’s future.”

 

European Commission Vice-President Jyrki Katainen, responsible for Jobs, Growth, Investment and Competitiveness, said: "I am delighted that the Investment Plan is contributing to ground-breaking research and development projects undertaken by Apeiron to develop new drug treatments. Today's agreement is a perfect demonstration of the real, tangible benefits that the Commission's commitment to promoting investment, research and innovation are producing."